Quantcast

Latest Amines Stories

2014-09-22 16:23:05

DUBLIN, September 22, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/lnlrtk/global_and ) has announced the addition of the "Global and Chinese Triethanolamine Industry Report 2014" [http://www.researchandmarkets.com/research/lnlrtk/global_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Global and Chinese Triethanolamine Industry Report 2014 is a professional and in-depth...

2014-09-22 14:14:40

Methadone has been used to treat opiate addiction in America for about 50 years, since Dr. Vincent Dole of New York’s Rockefeller University first discovered that the drug was able to relieve opiate withdrawal symptoms and allow addicts to return to their normal lives. Although numerous studies support the safety and efficacy of methadone maintenance for the treatment of opiate addiction, myths about methadone continue to thrive. If you or someone close to you is struggling with opiate...

2014-09-19 16:24:28

ReportsnReports.com adds "Market Research Report on Global and Chinese Oxybutynin Hydrochloride (CAS 1508-65-2) Industry, 2009-2019" to its store. DALLAS, Sept. 19, 2014 /PRNewswire-iReach/ -- Market Research Report on Global and Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Oxybutynin Hydrochloride industry. The report firstly reviews the basic information of Oxybutynin Hydrochloride including its...

2014-09-15 08:28:36

MONMOUTH JUNCTION, N.J., Sept. 15, 2014 /PRNewswire/ -- Vernalis plc (LSE: VER) and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has confirmed that the New Drug Application ("NDA") for Tuzistra(TM) XR ("CCP-01") has been accepted for full review. This triggers a milestone payment from Vernalis to Tris. The FDA has set a Prescription Drug User Fee Act (PDUFA) target date for conclusion of its review of 30 April 2015. Under...

2014-09-10 08:30:33

Key Step Accomplished Signals the Initiation of Clinical Development for Potential Blockbuster d-methadone NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCBB: RLMD) ("Relmada" or the "Company"), a clinical stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct 2 pharmacokinetic studies with d-methadone, its NMDA receptor antagonist for...

2014-09-09 08:31:52

Material Progress on All Fronts in 2014 Leave Company Strongly Positioned to Unlock the Value of its Robust Pain Product Pipeline NEW YORK, Sept. 9, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a Nevada corporation (the "Company") developing novel therapies for the treatment of chronic pain, today announced that is has filed its Form 10-K with the SEC, showing the Company's significant strides in 2014. The Company has made significant progress scientifically, financially...

2014-09-03 23:07:19

Responding to the scale of tramadol abuse, the DEA just reclassified the drug as a Schedule IV substance (effective Aug. 18/2014) yet despite a genuine need for information, no comprehensive guide to safely tapering and managing withdrawals existed. Choose Help’s new free downloadable eBook, How To Quit Tramadol, fills this information void as the world’s first complete guide to overcoming tramadol addiction and managing withdrawal symptoms. Los Angeles, California (PRWEB) September...

2014-09-03 23:03:24

DeepResearchReports.com adds “2014 Deep Research Report on Global and China Triethanolamine Industry” report to its research store. Dallas, Texas (PRWEB) September 03, 2014 This is a professional and in-depth study on the current state of the Triethanolamine Industry in Global and China. The report provides a basic overview of the industry, including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a...

2014-09-02 20:24:44

- Primary efficacy endpoint met with a statistically significant reduction of sIGF-I levels of 26% at the 400mg/week dose (P

2014-08-27 08:27:34

MONMOUTH JUNCTION, N.J., Aug. 27, 2014 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that it has been selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence competition in the Business Expansion category. Finalists were selected by an independent panel of judges from SCORE (Counselors to America's Small Business) and NJBIA member...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related